Skip to main navigation
Disability accessibility tool
  • Contact Us
Neurocrine Biosciences logo
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
  • Your Health
    • Diseases & Conditions
    • Approved Medicines
    • TD Awareness
    • Investigational Therapies
  • Our Science
    • Approved Medicines
    • Pipeline
    • Clinical Studies
  • Our Company
    • About Us
    • Leadership
    • News & Media
    • Our Responsibility
    • DE&I
    • Grants & Sponsorships
  • Investors
    • Investor Overview
    • Stock Information
    • Financial Communications
    • Governance
    • Sustainability
    • Business Development
    • Webcasts & Presentations
  • Careers
    • Meet Our People
    • Work with Us
    • Explore Our Benefits
+
  • Investor Overview
  • Stock Information
    • Stock Quote
    • Shareholder Contacts
    • Analyst Coverage
  • Financial Communications
    • SEC Filings
    • Annual Meeting
    • Annual Reports
  • News Releases
  • Corporate Governance
  • Sustainability
  • Business Development
  • Webcasts & Presentations

Investor Overview

Latest News Releases

View All
9/21/23
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
Read More
9/14/23
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
Read More
9/12/23
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
Read More

2022 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)
  • Change
  • Volume
  • 52 Week High
  • 52 Week Low

09/11/23 5:28 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date Form Description Filing Group View
09/14/23 4

Statement of changes in beneficial ownership of securities

3,4,5
View HTML
0001209191-23-049448.pdf
0001209191-23-049448.rtf
0001209191-23-049448.xls
09/12/23 8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML
0000914475-23-000062.pdf
0000914475-23-000062.rtf
0000914475-23-000062.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
09/12/23 144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
View HTML
0001950047-23-003936.pdf
0001950047-23-003936.rtf

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report

Email Alerts

Sign up to automatically receive Neurocrine Biosciences financial information by email

Sign Up Now

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

 
Neurocrine logo
  • Diseases & Conditions
  • News & Media
  • Approved Medicines
  • Careers
  • Investigational Therapies
  • Leadership
  • Pipeline
  • Investors
  • Clinical Studies
  • Our Responsibility
Follow Us
Facebook logo
Linkedin logo
Twitter logo
©2022 Neurocrine Biosciences, Inc. All rights reserved.
 
  • Contact
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Accessibility
  • Sitemap